Interventional treatment for unresectable hepatocellular carcinoma

Murata, Satoru; Mine, Takahiko; Sugihara, Fumie; Yasui, Daisuke; Yamaguchi, Hidenori; Ueda, Tatsuo; Onozawa, Shiro; Kumita, Shin‐ichiro

doi:10.3748/wjg.v20.i37.13453

Cited by 39 publications

(29 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapy for HCC is still inefficacious. The tyrosine kinase inhibitor, Sorafenib, despite its limitations, such as low overall response rates and high toxicity, was the first systemic targeted therapy approved by the US Food and Drug Administration for the treatment of advanced HCC [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer

et al. 2016

View full text Add to dashboard Cite

Autophagy is a homeostatic, catabolic degradation process and cell fate essential regulatory mechanism. Protracted autophagy triggers cell death; its aberrant function is responsible for several malignancies. Panobinostat, a potent pan-deacetylase inhibitor, causes endoplasmic reticulum stress-induced cell death. The aim of this study was to investigate the role of autophagy in deacetylase inhibitor-triggered liver cancer cell death.HepG2 (p53wt) and Hep3B (p53 null) liver cancer cell lines were exposed to panobinostat. RT-qPCR and western blot confirmed autophagic factor modulation. Immuno-fluorescence, -precipitation and -histochemistry as well as transmission electron microscopy verified autophagosome formation. The cytotoxicity of panobinostat and autophagy modulators was detected using a real time cell viability assay.Panobinostat induced autophagy-related factor expression and aggregation. Map1LC3B and Beclin1 were significantly over-expressed in HepG2 xenografts in nude mice treated with panobinostat for 4 weeks. Subcellular distribution of Beclin1 increased with the appearance of autophagosomes-like aggregates. Cytosolic loss of p53, in HepG2, and p73, in Hep3B cells, and a corresponding gain of their nuclear level, together with modulation of DRAM1, were observed. Autophagosome aggregation was visible after 6 h of treatment. Treatment of cells stably expressing GFP-RFPtag Map1LC3B resulted in aggregation and a fluorescence switch, thus confirming autophagosome formation and maturation. Tamoxifen, an inducer of autophagy, caused only a block in cell proliferation; but in combination with panobinostat it resulted in cell death.Autophagy triggers cell demise in liver cancer. Its modulation by the combination of tamoxifen and panobinostat could be a new option for palliative treatment of hepatocellular carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Modified TACE procedures, such as superselective TACE, selective balloon-occluded TACE, and TACE under balloon occlusion of the hepatic vein or the corresponding portal vein branch, have been developed to obtain a complete necrosis of the tumor [121]. Alternative strategies, including the combination of systemic therapy with TACE, have also been investigated to improve TACE-based regimens.…”

Section: Transarterial Therapymentioning

confidence: 99%

A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma

Shi

Zhai

2016

Gastrointest Tumors

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related deaths. Hepatic resection and liver transplantation are considered to be the preferred treatment for HCC. However, as novel therapeutic options such as image-guided locoregional therapies have emerged and been refined, the manner in which HCC is treated has changed dramatically compared with what it was considered just 2 decades earlier. Summary: This study reviews the current results of various image-guided locoregional therapies for treating HCC, especially focusing on thermal ablative and transarterial techniques. Key Message: Advances in image-guided locoregional therapies, including local ablative therapy and transarterial therapy, have led to a major breakthrough in the management of HCC. Both survival rates and cure rates of patients with HCC have improved markedly since the introduction of these techniques. Practical Implications: Radiofrequency ablation is currently considered as an alternative to surgical resection for patients with early-stage HCC. A newer technique of ablation such as microwave ablation is increasingly being used, especially for large HCC. Transarterial chemoembolization has become a standard care for asymptomatic patients with multinodular tumors in intermediate-stage disease, and transarterial radioembolization has become the method of choice in HCC cases with portal vein thrombosis. Moreover, combination treatment modalities, such as thermal-based ablation combined with transarterial chemoembolization or ¹²⁵I seed implant brachytherapy, may further broaden their clinical indications for HCC. Moreover, use of localized radiation in combination with thermal ablation has been reported to improve tumor control and long-term survival.

show abstract

“…For example, incomplete HCC treatment via TACE can result in increased levels of angiogenic factors, leading to tumor growth and metastasis. 139 A novel study conducted by the MD Anderson Cancer Center Group demonstrated that machine learning may play a role in predicting patient response to TACE using quantitative imaging features in combination with the BCLC staging system. 140 Other machine learning applications in interventional oncology include intraprocedural support, such as catheter guidance, and postprocedural assessment, such as posttreatment MRI-based texture analysis of tumors.…”

Section: Future Therapiesmentioning

confidence: 99%

Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions

Bajwa

Madoff

Kishore

2020

Digestive Disease Interventions

View full text Add to dashboard Cite

Primary and secondary liver cancers are a major cause of mortality worldwide. Transarterial liver-directed therapy, or embolotherapy, represents an important locoregional treatment strategy for primary and secondary liver tumors. Embolotherapeutic modalities include bland embolization (transarterial embolization), chemoembolization (transarterial chemoembolization), and radioembolization or selective internal radiotherapy. A brief technical overview of embolotherapeutic modalities as well as supportive evidence for the treatment of most common primary and secondary liver tumors will be discussed in this review. Several potential future applications, including synergy with systemic therapy, interventional theranostics, and artificial intelligence will also be reviewed briefly.

show abstract

Interventional treatment for unresectable hepatocellular carcinoma

Cited by 39 publications

References 102 publications

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer

A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma

Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions

Contact Info

Product

Resources

About